272 related articles for article (PubMed ID: 35892829)
1. The Role of PIM Kinases in Pediatric Solid Tumors.
Julson JR; Marayati R; Beierle EA; Stafman LL
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892829
[TBL] [Abstract][Full Text] [Related]
2. Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma.
Stafman LL; Williams AP; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Beierle EA
Transl Oncol; 2019 Feb; 12(2):200-208. PubMed ID: 30412911
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects.
Rathi A; Kumar D; Hasan GM; Haque MM; Hassan MI
Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129995. PubMed ID: 34455019
[TBL] [Abstract][Full Text] [Related]
4. Potential Pharmacological Inhibitors of Pim Kinase Under Clinical Trials.
Jeyapal GP; Chandrasekar MJN; Krishnasamy R; Selvaraj J; Mohammad M; Nanjan MJ
Anticancer Agents Med Chem; 2018; 18(8):1100-1114. PubMed ID: 29384063
[TBL] [Abstract][Full Text] [Related]
5. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
[TBL] [Abstract][Full Text] [Related]
6. Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.
Stafman LL; Mruthyunjayappa S; Waters AM; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Mroczek-Musulman E; Beierle EA
Oncotarget; 2018 Apr; 9(32):22665-22679. PubMed ID: 29854306
[TBL] [Abstract][Full Text] [Related]
7. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
Yang Q; Chen LS; Gandhi V
Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
[TBL] [Abstract][Full Text] [Related]
8. Pim kinases in hematological malignancies: where are we now and where are we going?
Mondello P; Cuzzocrea S; Mian M
J Hematol Oncol; 2014 Dec; 7():95. PubMed ID: 25491234
[TBL] [Abstract][Full Text] [Related]
9. The PIM family of serine/threonine kinases in cancer.
Narlik-Grassow M; Blanco-Aparicio C; Carnero A
Med Res Rev; 2014 Jan; 34(1):136-59. PubMed ID: 23576269
[TBL] [Abstract][Full Text] [Related]
10. The PIM kinases in hematological cancers.
Alvarado Y; Giles FJ; Swords RT
Expert Rev Hematol; 2012 Feb; 5(1):81-96. PubMed ID: 22272708
[TBL] [Abstract][Full Text] [Related]
11. PIM Kinase as an Executional Target in Cancer.
Zhang X; Song M; Kundu JK; Lee MH; Liu ZZ
J Cancer Prev; 2018 Sep; 23(3):109-116. PubMed ID: 30370255
[TBL] [Abstract][Full Text] [Related]
12. PIM Kinases in Multiple Myeloma.
Wu J; Chu E; Kang Y
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503111
[TBL] [Abstract][Full Text] [Related]
13. Targeting Pim kinases in hematological cancers: molecular and clinical review.
Bellon M; Nicot C
Mol Cancer; 2023 Jan; 22(1):18. PubMed ID: 36694243
[TBL] [Abstract][Full Text] [Related]
14. Targeting PIM Kinases to Improve the Efficacy of Immunotherapy.
Clements AN; Warfel NA
Cells; 2022 Nov; 11(22):. PubMed ID: 36429128
[TBL] [Abstract][Full Text] [Related]
15. Topical advances in PIM kinases and their inhibitors: Medicinal chemistry perspectives.
Walhekar V; Bagul C; Kumar D; Muthal A; Achaiah G; Kulkarni R
Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188725. PubMed ID: 35367531
[TBL] [Abstract][Full Text] [Related]
16. Targeting Pim kinases for cancer treatment: opportunities and challenges.
Le BT; Kumarasiri M; Adams JR; Yu M; Milne R; Sykes MJ; Wang S
Future Med Chem; 2015; 7(1):35-53. PubMed ID: 25582332
[TBL] [Abstract][Full Text] [Related]
17. Novel Pan-Pim Kinase Inhibitors With Imidazopyridazine and Thiazolidinedione Structure Exert Potent Antitumor Activities.
Sawaguchi Y; Yamazaki R; Nishiyama Y; Mae M; Abe A; Nishiyama H; Nishisaka F; Ibuki T; Sasai T; Matsuzaki T
Front Pharmacol; 2021; 12():672536. PubMed ID: 34012401
[TBL] [Abstract][Full Text] [Related]
18. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.
Blanco-Aparicio C; Carnero A
Biochem Pharmacol; 2013 Mar; 85(5):629-643. PubMed ID: 23041228
[TBL] [Abstract][Full Text] [Related]
19. The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms.
Isaac M; Siu A; Jongstra J
Drug Resist Updat; 2011; 14(4-5):203-11. PubMed ID: 21601509
[TBL] [Abstract][Full Text] [Related]
20. PIM kinases: From survival factors to regulators of cell motility.
Santio NM; Koskinen PJ
Int J Biochem Cell Biol; 2017 Dec; 93():74-85. PubMed ID: 29108877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
